SGLT2 inhibitors change blood pressure, affect renal outcomes in T2DM
In type 2 diabetes mellitus (T2DM) patients, the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors reduces blood pressure which, in turn, influences renal outcomes, a new Japan study has found.